Metrika

  • citati u SCIndeksu: [4]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:13
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 1 od 1  
2012, vol. 31, br. 3, str. 239-245
Hiperfosfatemija - faktor rizika za razvoj nepovoljnog ishoda kod bolesnika koji se leče redovnim hemodijalizama
aKlinički centar Kragujevac, Klinika za urologiju, nefrologiju i dijalizu
bKlinički centar Srbije, Centar za medicinsku biohemiju, Beograd
cUniverzitet u Beogradu, Medicinski fakultet, KBC 'Dr Dragiša Mišović'
dKlinički centar Srbije, Klinika za urologiju, Beograd

e-adresaaca96@eunet.rs
Projekat:
Biomarkeri oštećenja i disfunkcije organa (MPNTR - 175036)

Ključne reči: hemodijaliza; hiperfosfatemija; kardiovaskularni mortalitet
Sažetak
Hiperfosfatemija ima značajnu ulogu u kalcifikaciji srčanih valvula i koronarnih arterija bolesnika na hemodijalizi. Radi utvrđivanja prevalencije hiperfosfatemije i ispitivanja njenog uticaja na ishod bolesnika koji se leče redovnim hemodijalizama, ispitano je 115 bolesnika koji se leče redovnim hemodijalizama duže od 6 meseci. Laboratorijsko ispitivanje je sprovedeno na početku, posle 12 i 24 meseci praćenja bolesnika. Kalcifikacija srčanih valvula je procenjivana ehokardiografskom metodom. Za statističku analizu podataka korišćeni su jednofaktorska parametarska analiza varijanse - ANOVA i analiza preživljavanja (Kaplan-Meier test, Log-Rank test). Hiperfosfatemiju ima 31,30% bolesnika, povećan proizvod solubiliteta 36,52% bolesnika, a kalcifikaciju srčanih valvula 48,70% bolesnika. Bolesnici kod kojih je na početku ispitivanja koncentracija fosfata u serumu >2,10 mmol/L i pro izvod solubiliteta >5,65 mmol2/L2 imaju visok rizik za razvoj opšteg i kardiovaskularnog mortaliteta. Hiperfosfatemija je faktor rizika za razvoj nepovoljnog ishoda kod bolesnika koji se leče redovnim hemodijalizama.
Reference
Aronow, W.S. (2009) Acute and chronic management of atrial fibrillation in patients with late-stage CKD. American journal of kidney diseases, 53(4): 701-10
Block, G.A., Raggi, P., Bellasi, A., Kooienga, L., Spiegel, D.M. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International, 71(5): 438-441
Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M. (2004) Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. Journal of the American Society of Nephrology, 15(8): 2208-2218
Block, G.A. (2001) Control of serum phosphorus: Implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Current opinion in nephrology and hypertension, 10(6): 741-7
Block, G., Port, F.K. (2003) Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial, 16(2): 140-7
Block, G.A., Spiegel, D.M., Ehrlich, J., Mehta, R., Lindbergh, J., Dreisbach, A., Raggi, P. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney international, 68(4): 1815-24
Bushinsky, D.A., Messa, P. (2008) Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients. NDT plus, 1(Suppl 1): 18-23
Cannata-Andia, J.B., Carrera, F. (2008) The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. Nephrol Dial Transplant, 1(Suppl 1), str. 29-35
Chertow, G.M., Blumenthal, S., Turner, S., Roppolo, M., Stern, L., Chi, E.M. (2006) Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate. Clinical Journal of the American Society of Nephrology, 1(2): 305-312
Chertow, G.M., Pupim, L.B., Block, G.A., Correa-Rotter, R., Drueke, T.B., Floege, J., Goodman, W.G., London, G.M., Mahaffey, K.W., Moe, S.M., Wheeler, D.C., Albizem, M., Olson, K., Klassen, P., Parfrey, P. (2007) Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview. Clinical Journal of the American Society of Nephrology, 2(5): 898-905
Chertow, G.M., Burke, S.K., Raggi, P. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney international, 62(1): 245-52
de Broe, M.E. (2009) Phosphate: Despite advances in research, the benefits to patients remain limited. Kidney international, 75(9): 880-1
Đerić, M., Čabarkapa, V.S. (2010) Cardiovascular biomarkers in chronic kidney disease. Journal of Medical Biochemistry, vol. 29, br. 4, str. 298-303
Eddington, H., Klara, P.A. (2010) The association of chronic kidney disease: Mineral bone disorder and cardiovascular risk. J Ren Car, 36(Suppl 1), str. 61-7
Ganesh, S.K., Stack, A.G., Levin, N.W., Hulbert-Shearon, T., Port, F.K. (2001) Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology, 12(10): 2131-8
Giachelli, C.M. (2009) The emerging role of phosphate in vascular calcification. Kidney international, 75(9): 890-7
Goodman, W.G. (2004) The Consequences of Uncontrolled Secondary Hyperparathyroidism and Its Treatment in Chronic Kidney Disease. Seminars in Dialysis, 17(3): 209-216
Hörl, W.H. (2004) The clinical consequences of secondary hyperparathyroidism: Focus on clinical outcomes. Nephrol Dial Transplant, 19 Suppl 5: V2-8
Kanbay, M., Afsar, B., Goldsmith, D., Covic, A. (2010) Sudden Death in Hemodialysis: An Update. Blood Purification, 30(2): 135-145
Levin, N.W., Hoenich, N.A. (2001) Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Current opinion in nephrology and hypertension, 10(5): 563-8
Ležaić, V. (2010) Serum and urinary biomarkers determination and their significance in diagnosis of kidney diseases. Journal of Medical Biochemistry, vol. 29, br. 4, str. 288-297
London, G.M., Pannier, B., Marchais, S.J., Guerin, A.P. (2000) Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol, 11(4): 778-83
Messa, P., Macario, F., Yaqoob, M., Bouman, K., Braun, J., von Albertini, B., Brink, H., Maduell, F., Graf, H., Frazao, J.M., Bos, W.J., Torregrosa, V., Saha, H., Reichel, H., Wilkie, M., Zani, V.J., Molemans, B., Carter, D., Locatelli, F. (2008) The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology, 3(1): 36-45
Murer, H., Hernando, N., Forster, I., Biber, J. (2000) Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiological reviews, 80(4): 1373-409
Parfrey, P.S. (2000) Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant, 15 Suppl 5: 58-68
Petrović, D., Stojimirović, B. (2008) Kardiovaskularni morbiditet i mortalitet bolesnika na hemodijalizi - epdiemiološka analiza. Vojnosanitetski pregled, vol. 65, br. 12, str. 893-900
Petrović, D., Obrenović, R., Trbojević-Stanković, J., Majkić-Singh, N., Stojimirović, B. (2011) Cardiovascular mortality in hemodialysis patients: Clinical and epidemiological analysis. Journal of Medical Biochemistry, vol. 30, br. 4, str. 302-308
Petrović, D., Stojimirović, B. (2010) Sekundarni hiperparatiroidizam faktor rizika za razvoj kardiovaskularnih komplikacija kod bolesnika na hemodijalizi. Medicinski pregled, vol. 63, br. 9-10, str. 674-680
Petrović, D., Obrenović, R., Stojimirović, B. (2009) Risk factors for aortic valve calcification in patients on regular hemodialysis. International journal of artificial organs, 32(3): 173-9
Prié, D., Ureña, T.P., Friedlander, G. (2009) Latest findings in phosphate homeostasis. Kidney international, 75(9): 882-9
Prié, D., Beck, L., Urena, P., Friedlander, G. (2005) Recent findings in phosphate homeostasis. Current opinion in nephrology and hypertension, 14(4): 318-24
Qunibi, W.Y. (2004) Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int, 66 (Suppl 90): 8-12
Ribeiro, S., Ramos, A., Brandão, A., Rebelo, J.R., Guerra, A., Resina, C., Vila-Lobos, A., Carvalho, F., Remédio, F., Ribeiro, F. (1998) Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrology, dialysis, transplantation, 13(8): 2037-40
Rufino, M., García, S., Jiménez, A., Alvarez, A., Miquel, R., Delgado, P., Marrero, D., Torres, A., Hernández, D., Lorenzo, V. (2003) Heart valve calcification and calcium x phosphorus product in hemodialysis patients: Analysis of optimum values for its prevention. Kidney Int Suppl, (85): S115-8
Toussaint, N.D., Kerr, P.G. (2007) Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology, 12(5): 500-9
Ventura, J.E., Tavella, N., Romero, C., Petraglia, A., Báez, A., Muñoz, L. (2002) Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance haemodialysis. Nephrology, dialysis, transplantation, 17(10): 1795-801
Wolf, M. (2010) Forging Forward with 10 Burning Questions on FGF in Kidney Disease. J Am Soc Nephrol, 21(9); 906-14
Zebe, H. (2000) Atrial fibrillation in dialysis patients. Nephrology, dialysis, transplantation, 15(6): 765-8
Zoccali, C. (2006) Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney international, 70(1): 26-33
Zoccali, C., Mallamaci, F., Tripepi, G. (2003) Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney International, 63(s85): 105-110
Zoccali, C., Mallamaci, F., Tripepi, G. (2004) Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol, 15 Suppl 1: S77-80
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2478/v10011-012-0002-5
objavljen u SCIndeksu: 22.03.2013.